Abstract
This study aims to determine the effectiveness of mycophenolate sodium (MS) in patients with scleroderma (SSc)-related interstitial lung disease (ILD). In a prospective observational study, we evaluated 14 consecutive SSc-ILD patients who were treated with MS for 12 months. The effect of MS on lung function was examined by using longitudinal data analytic methods. Wilcoxon rank–sum tests were used to examine the forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) by pulmonary function testing. As a group, the median values for FVC, FEV1 and DLCO did not change significantly after 12 months of MS therapy and fulfilled the definition of stable disease by the American Thoracic Society. Individually, after 12 months of treatment, 6 out of 14 patients showed a pulmonary improvement defined as an increase of more than 10% in FVC, and 5 out of 14 patients remained stable. By contrast, the median FVC had declined a non-significant 7.2% from the previous 12 months before MS initiation. No significant drug adverse effects were registered. These prospective data suggest that MS is a safe and well-tolerated therapy for SSc-ILD patients, and it is capable of preventing functional pulmonary deterioration.
Similar content being viewed by others
References
White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin N Am 29:371–390
Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 28:2454–2459
Steen V, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444
Altman R, Medsger TA Jr, Bloch D, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413
Hubbard R, Venn A (2002) The impact of coexisting connective tissue disease on survival on patients with fibrosing alveolitis. Rheumatology (Oxford) 41:676–679
Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M et al (1992) Mortality in systemic sclerosis (scleroderma). Q J Med 298:139–148
Silver RM, Warrick JH, Kinsella M, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844
White B, Moore WC, Wigley FM, Hui Qing Xiao, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947–954
Tashkin DP, Elashoff R, Clements PJ, Scleroderma Lung Study (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666
Hoyles R, Ellis R, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomised, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970
Davas EM, Pepas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455–461
Varai G, Earle L, Jiménez SA, Steinert RM, Varga J (1998) A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 25:1325–1329
Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298–304
Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conferti ML et al (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731–736
Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371–2378
Mittal G, Udwadia Z, Joshi VR (2003) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 30:1121–1122
Airò P, Danieli E, Parrinello G, Frassi, Cavazzana I, Scarsi M et al (2004) Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 22:573–578
Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M et al (2005) Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 64:1343–1346
Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN et al (2007) Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27:357–361
Simeón CP, Fonollosa V, Tolosa C, Selva A, Solans R, Palliza E et al (2008) Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis related interstitial lung disease: a long term study. Open Respir Med J 2:39–45
Tahskhin D, Elashoff R, Clements P, SLR group (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026–1034
Liossis SN, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45:1005–1008
Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130:30–36
Zamora AC, Wolters PJ, Collard HR, Connolly K, Elicker B, Webb W et al (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102:150–155
Gerbino A, Goss C, Molitor J (2008) Effect of mycohenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455–460
Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas L (2010) Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 10:1167–1168
Vanthuyne M, Bockmans D, Westhovens R, Roufosse F, Cogan E, Coche E et al (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25:287–292
Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanism of action. Immunopharmacology 47:85–118
Appel GB, Radhakrishnan J, Ginzler EM (2005) Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 80(2 Suppl):S265–S271
Shimizu H, Takahashi M, Takeda S, Inoue S, Fujishiro J, Hakamata Y et al (2004) Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 77:1661–1667
Guo H, Leung JC, Chan LY et al (2005) Modulation of intrapulmonary TGF-ß expression by mycophenolate mofetil in lupus prone MRL/pr mice. Lupus 14:583–592
Budde K, Curtis J, Knoll G (2004) Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplantation 4:237–243
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 23:581–590
LeRoy EC, Black C, Fleishmayer R, Jablonska S, Krieg T, Medsger TA et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–208
Simeón CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C et al (1997) Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 56:723–728
Roca J, Sanchis J, Agustí-Vidal A, Segarra F, Navajas D, Rodríguez-Roisin R et al (1986) Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir 22:217–224
American Thoracic Society (ATS) (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646–664
Antoniou KM, Wells AU (2008) Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 20:686–691
Behr J, Furst DE (2008) Pulmonary function tests. Rheumatology (Oxford) 47(Suppl 5):v65–v67
Nihtyanova SI, Brogh GM, Black CM, Denton CP (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 46:442–445
Derk, Grace E, Shenin M, Naik M, Schultz S, Xiong W et al (2009) Rheumatology 48:1595–1599
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C. et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 30, 1393–1398 (2011). https://doi.org/10.1007/s10067-011-1823-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1823-1